What's Happening?
Specific Biologics, a biotechnology company, has been awarded a $1.8 million grant from Genome Canada and Ontario Genomics to develop a machine learning platform for its Dualase genome editing technology. This platform aims to accelerate the discovery
of Dualase editors, which are designed for precise in vivo genome editing. The Dualase platform is notable for its ability to target and collapse toxic DNA repeat expansions, such as those in the C9ORF72 gene linked to amyotrophic lateral sclerosis (ALS). The funding will support the integration of machine learning to enhance the platform's efficiency and precision, potentially leading to new treatments for genetic diseases.
Why It's Important?
The development of the Dualase platform represents a significant advancement in genome editing technology, with the potential to address high morbidity genetic diseases. By integrating machine learning, Specific Biologics aims to streamline the discovery process, reducing the time and cost associated with developing new genetic therapies. This could lead to breakthroughs in treating conditions like ALS, which currently have limited therapeutic options. The grant underscores the importance of innovative approaches in biotechnology and the role of computational tools in accelerating medical research.
What's Next?
Specific Biologics plans to use the grant to further develop its machine learning platform, which will be used to identify potent Dualase editors for various genetic targets. The company is focused on moving its lead program into clinical trials for ALS patients. The collaboration with Western University and the ongoing development of the Dualase platform could lead to new partnerships and expanded applications in other genetic diseases.
